MALT1 and neoplasm: The systemic MALT1 inhibition also enhanced anti-tumor immunity in a vaccination protocol with an increase in the activity of tumor-infiltrating IFN-γ-producing CD8+ and CD4+ T cells and a significant decrease in tumor size, although this treatment did not alter the frequency of Tregs within the tumor tissue (Fig. 7d–g, Supplementary Fig. 9a and b).